Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers without corporate access will find a wealth of contextualized life science insight ready to be purchased in the FENIX Marketplace. If our content sharing limitations are inconvenient for you, reach out to Brady for unlimited corporate, institutional, or individual access.
$599
Posted in: GLP-1RA, Other, Topics Mar 06 | 2026MiniMed Shares IPO Pricing; NMPA Approves Sciwind/Pfizer’s Ecnoglutide Injection in Obesity; Novo Appoints New SVPPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Insulin Delivery, Other, Topics Mar 05 | 2026Topline Petrelintide Ph2 Results; Potential Brand Name for Orforglipron?; New Novo Ph1 Obesity Asset; Altimmune and Lexicon Q4 ’25 Earnings; Lilly Launches New DTE Platform; Tandem Mobi Now Available on AndroidPurchase Blast
$599
Posted in: GLP-1RA, Other, Topics Mar 04 | 2026FDA Issues Warning Letters for Misleading Pharmaceutical Advertising; Veru Initiates Enobosarm Ph2b PLATEAU Study; Vanda Initiates Tradipitant Ph3 StudyPurchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery, Other, Topics Mar 03 | 2026Senseonics Q4 ’25 Earnings; BI Terminates Ph2 MASH ProgramPurchase Blast
$599
Posted in: GLP-1RA, Other, Topics Mar 02 | 2026Novo Expands Ireland Manufacturing Facility; QL Biopharm Raises $72M in Series CPurchase Blast
$599
Posted in: Bolus Insulin, GLP-1RA, Other, Topics Feb 27 | 2026Structure Q4 ’25 Earnings; February CHMP Meeting HighlightsPurchase Blast
$599
Posted in: Bolus Insulin, Dual/triple agonist, GLP-1RA, Insulin Delivery, Other, Topics Feb 27 | 2026Ionis, Wave, and MannKind Q4 ’25 Earnings; New Ph2 Olatorepatide Study; ACHIEVE-3 Full Results; MindRank Doses First Patient in Ph3 Oral GLP-1RA Study; Fractyl Completes Pivotal EnrollmentPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, Topics Feb 25 | 2026FDA Approves Biocon’s Generic Saxenda; Novo Partners for Oral Peptide Development; Medtronic Launches MiniMed Go in EU; Bloom Doses First Patient in Ph1 Obesity Trial; BreezeBio Raises $60M in Series B; Verdiva Completes Ph2b Obesity Enrollment; MHRA Raids Illegal Manufacturing Facilities in UKPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Feb 25 | 2026Obesity Power Rankings: Who Will Challenge Lilly and Novo? Purchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Feb 24 | 2026Novo Reduces Semaglutide WAC Prices; Pfizer To Commercialize Ecnoglutide in China; Novo Ph2 GGG data; AbbVie Builds Out Obesity Manufacturing; Fortress Sells PRV; Alveus Closes $197M Series A; Beta Bionics FDA Warning Letter; Hims & Hers Q4 ’25 EarningsPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, Topics Feb 23 | 2026Lilly Launches Zepbound KwikPen; Allurion Gains FDA Approval; Eversense 365 Launches with twiist AID System; February CHMP AgendaPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Feb 23 | 2026Cagrisema Gets RedefinedPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, Topics Feb 20 | 2026Tandem Q4 ’25 Earnings; Verdiva Obesity Pipeline Purchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Feb 19 | 2026Zealand and Madrigal Q4 ’25 Earnings; Novo Initiates Ph2 T2DM Study of Internal Triple-Agonist; Goodpath Expands Wegovy AccessPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA, Glucagon, Glucose Monitoring, Insulin Delivery, Other, Topics Feb 18 | 2026Beta Bionics and Insulet Q4 ’25 Earnings; Lilly Taltz+Zepbound PsO Combination Data; Zealand Ph1a Kv1.3 Inhibitor Topline ResultsPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Feb 17 | 2026Lilly Retatrutide Risk Mitigation; Medtronic CY Q4 ’25 Earnings; 7.2mg Wegovy EU Approval; Lilly Targets India for Manufacturing Hub; EC Approval of Myqorzo; Esperion and Alkem Reach Generic BA AgreementPurchase Blast
$599
Posted in: Autologous, Basal Insulin, GLP-1RA, Glucose Monitoring, Insulin Delivery, Topics Feb 14 | 2026Dexcom, Vertex, and Biocon Q4 ’25 Earnings; Lilly Stockpiles Orforglipron Ahead of Launch Purchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Feb 12 | 2026Viking’s Oral VK2735 Progresses to Ph3; Novo to Sell Wegovy Vials; Alnylam Q4 ’25 Earnings; Sanofi Appoints New CEOPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Feb 11 | 2026Madrigal Partners for siRNA MASH Program; Novo Initiates Ph2 Obesity Study for Triple Agonist; Eccogene Reports Topline Ph1b Elecoglipron Data; Ascletis Selects Another Obesity Candidate; Cascade Raises $72M; Hoth Shares Pre-Clinical Obesity/MASH DataPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Other, Topics Feb 10 | 2026AZ’s Oral GLP-1RA Progresses to Ph3; Kailera and Hengrui Ph2 Oral Ribupatide Data; Pfizer Registers VESPER-5; Ph3 Zenagamtide vs Semaglutide H2H Study; Sava Preliminary CGM Data Purchase BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact Brady.
